ClinicalTrials.gg

Program

Ketamine

Also written as “Ketamine Hydrochloride”, “Ketamine (0.25 mg/kg)” and “Ketamine (0.5 mg/kg)”.

Its studies are mostly in Depressive Disorder, Major · Depression · Schizophrenia · Depressive Disorder, Treatment-Resistant · Bipolar Disorder, led by 15 companies.

Furthest: phase 4, since Jun 22, 201220 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson50 open or runningphase 2since Jun 22, 2012Jul 15, 2010none ahead
Egymedicalpedia20 open or runningphase 1since Jun 21, 2022Jun 21, 2022none ahead
cch-pharmaceuticals10 open or runningphase 2since Nov 25, 2019Nov 25, 2019none ahead
dr-horst-schmidt-klinik-gmbh10 open or runningno phasesince Aug 12, 2016Aug 12, 2016none ahead
ehave-inc10 open or runningphase 4since Aug 9, 2022Aug 9, 2022none ahead
ERP Biomarker Qualification Consortium10 open or runningearly phase 1since May 28, 2021May 28, 2021none ahead
Field Trip Health10 open or runningphase 4since Oct 12, 2022Oct 12, 2022none ahead
Homeostasis Therapeutics10 open or runningphase 1since Jan 12, 2021Jan 12, 2021none ahead
javelin-pharmaceuticals10 open or runningphase 1since Apr 16, 2008Apr 16, 2008none ahead
NeuroRx11 open or runningphase 3since Jan 5, 2018Jan 5, 2018none ahead
neurowave-systems-inc10 open or runningphase 1since Dec 29, 2016Dec 29, 2016none ahead
PharmaTher10 open or runningphase 2since May 25, 2021May 25, 2021none ahead
Seelos Therapeutics10 open or runningphase 2since Dec 9, 2020Dec 9, 2020none ahead
Soterix Medical10 open or runningphase 1since Dec 15, 2025Dec 15, 2025none ahead
trudiagnostic10 open or runningphase 2since Mar 14, 2022Mar 14, 2022none ahead

Also a collaborator on its studies: target-health-inc, Alkermes, anavex-life-sciences-corp, Astellas Pharma, H. Lundbeck, Merck, Novartis, Supernus Pharmaceuticals and Takeda.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Apr 16, 2008.

  1. Dec 29, 2016neurowave-systems-inc's first study: phase 1 study in AnesthesiaNew to neurowave-systems-incneurowave-systems-inc · NCT03009409 · 60 enrolled · Canada
  2. Jan 5, 2018NeuroRx's first study: phase 3 study in Bipolar DisorderNew to NeuroRxNeuroRx · NCT03396601 · 150 enrolled · United States
  3. Jan 4, 2019Phase 1 study in HealthyJohnson & Johnson · NCT03808259 · 96 enrolled · Belgium
  4. Nov 25, 2019cch-pharmaceuticals's first study: phase 2 study in Cluster HeadacheNew to cch-pharmaceuticalscch-pharmaceuticals · NCT04179266 · 23 enrolled · Denmark
  5. Dec 9, 2020Seelos Therapeutics's first study: phase 2 study in Depressive Disorder, MajorNew to Seelos TherapeuticsSeelos Therapeutics · NCT04669665 · 164 enrolled · United States
  6. Jan 12, 2021Homeostasis Therapeutics's first study: phase 1 study in Anorexia NervosaNew to Homeostasis TherapeuticsHomeostasis Therapeutics · NCT04714541 · 5 enrolled · United States
  7. May 25, 2021PharmaTher's first study: phase 2 study in DyskinesiasNew to PharmaTherPharmaTher · NCT04912115 · 30 enrolled · United States
  8. May 28, 2021ERP Biomarker Qualification Consortium's first study: early phase 1 study in HealthyNew to ERP Biomarker Qualification ConsortiumERP Biomarker Qualification Consortium · NCT04928703 · 33 enrolled · United States
  9. Mar 14, 2022trudiagnostic's first study: phase 2 study in DepressionNew to trudiagnostictrudiagnostic · NCT05294835 · 20 enrolled · United States
  10. Jun 21, 2022Egymedicalpedia's first study: phase 1 study in SurgeryNew to EgymedicalpediaEgymedicalpedia · NCT05444036 · 60 enrolled · Egypt
  11. Aug 9, 2022ehave-inc's first study: phase 4 study in Depressive Disorder, MajorNew to ehave-incehave-inc · NCT05506462 · 35 enrolled
  12. Oct 12, 2022Field Trip Health's first study: phase 4 study in DepressionNew to Field Trip HealthField Trip Health · NCT05604794 · 1,806 enrolled · United States, Canada
  13. Oct 24, 2022Phase 1 study in NephrectomyEgymedicalpedia · NCT05596669 · 100 enrolled · Egypt
  14. Dec 15, 2025Soterix Medical's first study: phase 1 study in Depressive Disorder, Treatment-ResistantNew to Soterix MedicalSoterix Medical · NCT07307768 · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07307768Depressive Disorder, Treatment-Resistant · United States1WithdrawnSoterix MedicalDec 1, 20270
NCT05596669Nephrectomy · Egypt1CompletedEgymedicalpediaMay 1, 2022100
NCT05604794Depression · United States, Canada4CompletedField Trip HealthJun 16, 20221,806
NCT05506462Depressive Disorder, Major4UNKNOWNehave-incJan 202435
NCT05444036Surgery · Egypt1CompletedEgymedicalpediaMay 15, 201960
NCT05294835Depression · United States2UNKNOWNtrudiagnosticDec 31, 202220
NCT04928703Healthy · United StatesEarly 1CompletedERP Biomarker Qualification ConsortiumDec 12, 202233
NCT04912115Dyskinesias · United States2SuspendedPharmaTherDec 30, 202330
NCT04714541Anorexia Nervosa · United States1CompletedHomeostasis TherapeuticsJul 26, 20225
NCT04669665Depressive Disorder, Major · United States2CompletedSeelos TherapeuticsJun 17, 2023164
NCT04179266Cluster Headache · Denmark2Completedcch-pharmaceuticalsMay 12, 202023
NCT03808259Healthy · Belgium1CompletedJohnson & JohnsonSep 4, 201996
NCT03396601Bipolar Disorder · United States3Active, not recruitingNeuroRxDec 31, 2024150
NCT03009409Anesthesia · Canada1Completedneurowave-systems-incOct 17, 201860
NCT03105765Acute Pain · Germany–Completeddr-horst-schmidt-klinik-gmbhAug 2014200
NCT01957410Depressive Disorder, Major · United States2TerminatedJohnson & JohnsonSep 201513
NCT01809340Depressive Disorder · Belgium, France, Netherlands and more2TerminatedJohnson & JohnsonJul 201429
NCT01627782Depressive Disorder, Major · United States2CompletedJohnson & JohnsonSep 12, 201368
NCT01165294Schizophrenia1CompletedJohnson & Johnson24
NCT00662883Healthy · United States1Completedjavelin-pharmaceuticalsFeb 200818

How it is read

Names in the registry

  • “Ketamine”, 12 entries
  • “Ketamine Hydrochloride”, 2 entries
  • “Ketamine (0.25 mg/kg)”, 1 entry
  • “Ketamine (0.5 mg/kg)”, 1 entry
  • “Ketamine (0.75 mg/kg)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.